Clinical consequences of ADRbeta2 polymorphisms.

abstract：:This review deals with the pharmacological properties of an alkylated monosaccharide mimetic, N-butyldeoxynojirimycin (NB-DNJ). This compound is of pharmacogenetic interest because one of its biological effects in mice - impairment of spermatogenesis, leading to male infertility - depends greatly on the genetic backgr...

journal_title：Pharmacogenomics

authors： van der Spoel AC,Mott R,Platt FM

更新日期：2008-06-01 00:00:00

abstract：:The etiology of statin intolerance is hypothesized to be due to genetic variants that impact statin disposition and clearance. We sought to determine whether genetic variants were associated to statin intolerance. The studied cohort consisted of hyperlipidemic participants (n = 90) clinically diagnosed with statin int...

journal_title：Pharmacogenomics

authors： V Willrich MA,Kaleta EJ,Bryant SC,Spears GM,Train LJ,Peterson SE,Lennon VA,Kopecky SL,Baudhuin LM

更新日期：2018-01-01 00:00:00

abstract：:The recent advent of induced pluripotent stem cells has enabled the study of patient-specific and disease-related neurons in vitro and has facilitated new directions of inquiry into disease mechanisms. With these approaches, we now have the possibility of correlating ex vivo cellular phenotypes with individual patient...

journal_title：Pharmacogenomics

authors： Watmuff B,Liu B,Karmacharya R

更新日期：2017-04-01 00:00:00

abstract：:The completion of the first draft of the human genome sequence has revived the old notion that there is no one-to-one mapping between genotype and phenotype. It is now becoming clear that to elucidate the fundamental principles that govern how genomic information translates into organismal complexity, we must overcome...

journal_title：Pharmacogenomics

authors： Huang S

更新日期：2001-08-01 00:00:00

abstract：AIMS: AMPD1 c.34C > T (rs17602729) polymorphism results in AMPD1 deficiency. We examined the association of AMPD1 deficiency and variability of hemodynamic response to regadenoson. SUBJECTS & METHODS:Genotyping for c.34C>T was performed in 267 patients undergoing regadenoson cardiac stress testing. RESULTS:Carriers o...

journal_title：Pharmacogenomics

authors： Saab R,Zouk AN,Mastouri R,Skaar TC,Philips S,Kreutz RP

更新日期：2015-11-01 00:00:00

abstract：:RNA splicing is a tightly regulated process. It is essential for gene expression and, therefore, intervenes in every biological phenomenon in mammals. RNA splicing regulation is cell type-specific in such a way that a cellular situation can be characterised by its repertoire of spliced events, the spliceome. Compariso...

journal_title：Pharmacogenomics

authors： Schweighoffer F,Ait-Ikhlef A,Resink AL,Brinkman B,Melle-Milovanovic D,Laurent-Puig P,Kearsey J,Bracco L

更新日期：2000-05-01 00:00:00

abstract：:Translational research is frequently used in the bioscience literature to refer to the translation of basic science into practical applications at the point of patient care. With the introduction of theragnostics, a new medical subspecialty that fuses therapeutics and diagnostic medicine with the goal of providing ind...

journal_title：Pharmacogenomics

authors： Ozdemir V,Williams-Jones B,Cooper DM,Someya T,Godard B

更新日期：2007-02-01 00:00:00

abstract：:Human cytochrome P450 (CYP)3A is a major P450 enzyme found in the liver and gastrointestinal tract. It plays an important role in the metabolism of a wide variety of drugs, some endogenous steroids and harmful environmental contaminants. It has been shown that CYP3A alleles encoding enzymes with little or no activity ...

journal_title：Pharmacogenomics

authors： Liu CH,Peck K,Huang JD,Lin MS,Wang CH,Hsu WP,Wang HW,Lee HL,Lai ML

更新日期：2005-10-01 00:00:00

abstract：INTRODUCTION:One of the causes of long-term morbidity associated with the treatment of acute lymphoblastic leukemia (ALL) is late neurotoxicity manifesting as impairment of higher cognitive functions. Cranial radiation therapy (CRT) and chemotherapeutic agents, particularly methotrexate (MTX), are often suggested to be...

journal_title：Pharmacogenomics

authors： Krajinovic M,Robaey P,Chiasson S,Lemieux-Blanchard E,Rouillard M,Primeau M,Bournissen FG,Moghrabi A

更新日期：2005-04-01 00:00:00

abstract：:The pharmacokinetic and pharmacodynamic disciplines address pharmacological traits, including efficacy and adverse events. Pharmacogenomics studies have identified pervasive genetic effects on treatment outcomes, resulting in the development of genetic biomarkers for optimization of drug therapy. Pharmacogenomics-base...

journal_title：Pharmacogenomics

authors： Chhibber A,Kroetz DL,Tantisira KG,McGeachie M,Cheng C,Plenge R,Stahl E,Sadee W,Ritchie MD,Pendergrass SA

更新日期：2014-12-01 00:00:00

abstract：AIM:Based on previous pharmacogenetic findings, we investigated the possible association between SULT4A1-1 haplotype and antipsychotic treatment response. MATERIALS & METHODS:Using Mixed Model Repeated Measures, we tested the relationship between SULT4A1-1 status (+carrier, -noncarrier) and clinical improvement (in Po...

journal_title：Pharmacogenomics

authors： Wang D,Li Q,Favis R,Jadwin A,Chung H,Fu DJ,Savitz A,Gopal S,Cohen N

更新日期：2014-01-01 00:00:00

abstract：:Drug-induced liver injury (DILI) is an increasing health problem and a challenge for physicians, regulatory bodies and the pharmaceutical industry, not only because of its potential severity and elusive pathogenesis but also because it is often inaccurately diagnosed, commonly missed entirely and more often not report...

journal_title：Pharmacogenomics

authors： Andrade RJ,Robles M,Ulzurrun E,Lucena MI

更新日期：2009-09-01 00:00:00

abstract：:Aim: The need for pharmacogenomic education is becoming more and more urgent. Our aim was to evaluate the progress in pharmacogenomics education since then, and to put forward further recommendations. Methods: A survey was sent to 248 schools of medicine, pharmacy, nursing and health professions around the world. Resu...

journal_title：Pharmacogenomics

authors： Karas Kuželički N,Prodan Žitnik I,Gurwitz D,Llerena A,Cascorbi I,Siest S,Simmaco M,Ansari M,Pazzagli M,Di Resta C,Brandslund I,Schwab M,Vermeersch P,Lunshof JE,Dedoussis G,Flordellis CS,Fuhr U,Stingl JC,van Schaik RH

更新日期：2019-06-01 00:00:00

abstract：:The extent of genetic variation found in drug metabolism genes and its contribution to interindividual variation in response to medication remains incompletely understood. To better determine the identity and frequency of variation in 11 phase I drug metabolism genes, the exons and flanking intronic regions of the cyt...

journal_title：Pharmacogenomics

authors： Solus JF,Arietta BJ,Harris JR,Sexton DP,Steward JQ,McMunn C,Ihrie P,Mehall JM,Edwards TL,Dawson EP

更新日期：2004-10-01 00:00:00

abstract：AIM:We examined whether HLA-DRB1*1501 and four VDR SNPs influence the macrophage response to infection with Mycobacterium tuberculosis (Mtb) via innate immune versus drug treatment or drug delivery mechanisms. MATERIALS & METHODS:Monocyte-derived macrophages from 24 healthy donors were infected with Mtb in vitro. Surv...

journal_title：Pharmacogenomics

authors： Singh AK,Abhimanyu,Yadav AB,Sharma S,Garg R,Bose M,Misra A

更新日期：2013-04-01 00:00:00

abstract：:The narrow therapeutic range and wide interpatient variability in dose requirement make anticoagulation response to coumarin derivatives unpredictable. As a result, patients require frequent monitoring to avert adverse effects and maintain therapeutic efficacy. Polymorphisms in VKORC1 and CYP2C9 jointly account for ab...

journal_title：Pharmacogenomics

authors： van Schie RM,Wadelius MI,Kamali F,Daly AK,Manolopoulos VG,de Boer A,Barallon R,Verhoef TI,Kirchheiner J,Haschke-Becher E,Briz M,Rosendaal FR,Redekop WK,Pirmohamed M,Maitland van der Zee AH

更新日期：2009-10-01 00:00:00

abstract：:Arylamine N-acetyltransferases (NATs) catalyze the transfer of an acetyl group from acetyl-CoA to arylhydrazines and to arylamine drugs and carcinogens or to their N-hydroxylated metabolites. NAT plays an important role in detoxification and metabolic activation of xenobiotics and was first identified as the enzyme re...

journal_title：Pharmacogenomics

authors： Pompeo F,Brooke E,Kawamura A,Mushtaq A,Sim E

更新日期：2002-01-01 00:00:00

abstract：:Damage to the heart can result from both traditional chemotherapeutic agents, such as doxorubicin, and newer 'targeted' therapies, such as trastuzumab. This chemotherapeutic cardiotoxicity is potentially life-threatening and necessitates limiting or discontinuing an otherwise-effective cancer treatment. Clinical strat...

journal_title：Pharmacogenomics

authors： Jensen BC,McLeod HL

更新日期：2013-01-01 00:00:00

abstract：:This review will summarize the role of pharmacogenetics in the natural history of hepatitis C, particularly in patients with HIV/HCV and will take the perspective of pharmacogenetics and its influence on the response to antiviral therapy and the susceptibility to develop adverse effects. This review will also devote a...

journal_title：Pharmacogenomics

authors： Frias M,Rivero-Juárez A,López-López P,Rivero A

更新日期：2018-08-01 00:00:00

abstract：:Aim: To determine if selected serotonergic and noradrenergic gene variants are associated with heroin addiction. Subjects & methods: A total of 126 variants in 19 genes in subjects with Dutch European ancestry from The Netherlands. Subjects included 281 opioid-dependent volunteers in methadone maintenance or heroin-as...

journal_title：Pharmacogenomics

authors： Randesi M,van den Brink W,Levran O,Blanken P,van Ree JM,Ott J,Kreek MJ

更新日期：2019-04-01 00:00:00

abstract：AIM:We conducted a genome-wide association study using the Illumina Exome Array to identify coding SNPs that may explain additional warfarin dose variability. PATIENTS & METHODS:Analysis was performed after adjustment for clinical variables and genetic factors known to influence warfarin dose among 1680 warfarin users...

journal_title：Pharmacogenomics

authors： Liu N,Irvin MR,Zhi D,Patki A,Beasley TM,Nickerson DA,Hill CE,Chen J,Kimmel SE,Limdi NA

更新日期：2017-07-01 00:00:00

abstract：AIM:This study aimed to assess the effectiveness of genotype-guided warfarin dosing. PATIENTS & METHODS:A total of 109 adults were randomized to receive initial dosing as determined by an algorithm containing genetic (VKORC1 and CYP2C9) plus clinical information or only clinical information. Primary end points were th...

journal_title：Pharmacogenomics

authors： Jonas DE,Evans JP,McLeod HL,Brode S,Lange LA,Young ML,Shilliday BB,Bardsley MM,Swinton-Jenkins NJ,Weck KE

更新日期：2013-10-01 00:00:00

abstract：:The successful application of pharmacogenetics in routine clinical practice is still a long way from becoming a reality. In order to favor the transfer of pharmacogenetic results to clinical practice, especially in psychiatry, these studies must be optimized. This article reviews the strengths and weaknesses that char...

journal_title：Pharmacogenomics

authors： Mas S,Llerena A,Saíz J,Bernardo M,Lafuente A

更新日期：2012-11-01 00:00:00

abstract：:Pharmacogenomic analyses will become crucial to predict patients' toxicity to treatment and will also help to predict the tumor response. Processes of drug metabolism, drug efflux, DNA-repair and characteristics of drug targets are critical checkpoints of drug efficacy. These crucial pathways for drug action have been...

journal_title：Pharmacogenomics

authors： Stoehlmacher J,Goekkurt E,Lenz HJ

更新日期：2003-11-01 00:00:00

abstract：:miRNAs are reported to sequence-specifically control the translation of target mRNAs by binding to 3 UTRs. The abundant expression of miRNAs in the brain highlights their biological significance in neurodevelopment. Many studies have shown that miRNAs are involved in a variety of functions, including developmental tra...

journal_title：Pharmacogenomics

authors： Singh SK

更新日期：2007-08-01 00:00:00

abstract：:The current paradigm of human genetics research is to analyze variation of a single data type (i.e., DNA sequence or RNA levels) to detect genes and pathways that underlie complex traits such as disease state or drug response. While these studies have detected thousands of variations that associate with hundreds of co...

journal_title：Pharmacogenomics

authors： Holzinger ER,Ritchie MD

更新日期：2012-01-01 00:00:00

abstract：:The human µ-opioid receptor variant 118 A>G (rs1799971) has become one of the most analyzed genetic variants in the pain field. At the molecular level, the variant reduces opioid receptor signaling efficiency and expression, the latter probably via a genetic-epigenetic interaction. In experimental settings, the varian...

journal_title：Pharmacogenomics

authors： Walter C,Doehring A,Oertel BG,Lötsch J

更新日期：2013-11-01 00:00:00

abstract：:The advent of genome-wide association studies has allowed considerable progress in the identification and robust replication of common gene variants that confer susceptibility to common diseases and other phenotypes of interest. These genetic effect sizes are almost invariably moderate to small in magnitude and single...

journal_title：Pharmacogenomics

authors： Zeggini E,Ioannidis JP

更新日期：2009-02-01 00:00:00

abstract：:Recent research highlighted the large extent of rare variants in pharmacogenes and, on this basis, it was estimated that rare variants account for 30-40% of the functional variability in pharmacogenes. It has been proposed that comprehensive next-generation sequencing (NGS)-based sequencing of pharmacogenes could soon...

journal_title：Pharmacogenomics

authors： Lauschke VM,Ingelman-Sundberg M

更新日期：2016-06-01 00:00:00

abstract：:The heterogeneous Brazilian population, with European, African and Amerindian ancestral roots is a model case for exploring the impact of population admixture on the frequency distribution of polymorphisms in pharmacogenes, and the design and interpretation of pharmacogenomics trials. Examples drawn from studies carri...

journal_title：Pharmacogenomics

authors： Suarez-Kurtz G,Paula DP,Struchiner CJ

更新日期：2014-02-01 00:00:00